Jay Chhablani, MD

Articles by Jay Chhablani, MD

Jay Chhablani, MD, reviews late-breaking findings from the ArMaDa trial

October 9th 2025

The Phase 1/2 ArMaDa trial is evaluating OCU410 (Ocugen), a gene therapy candidate for patients with dry age-related macular degeneration.

Q&A: Jay Chhablani, MD, on the phase 1/2 data for OCU410 from ASRS 2025

ByJay Chhablani, MD,Sydney M Crago,Martin David Harp

August 6th 2025

3D choroidal vessel imaging offers new insights into retinal diseases

ByJay Chhablani, MD,Sydney M Crago

June 6th 2025

Retina specialist Jay Chhablani, MD, discusses 3D choroidal vessel segmentation, uncovering critical insights into macular degeneration, diabetic retinopathy, and potential systemic disease connections using advanced OCT technology.

Jay Chhablani, MD

Articles by Jay Chhablani, MD

Jay Chhablani, MD, reviews late-breaking findings from the ArMaDa trial

Q&A: Jay Chhablani, MD, on the phase 1/2 data for OCU410 from ASRS 2025

3D choroidal vessel imaging offers new insights into retinal diseases

Latest Updated Articles

Trending on Modern Retina

Pipeline update: Catch up on recent updates in the retina pipeline

AAO 2025: The safety and efficacy of oral gildeuretinol in participants with intermediate-stage Stargardt disease